Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study Fleischmann et al.

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00161-3/fulltext Fleischmann et al. https://www.thelancet.com/journals/lanrhe/home